TY - JOUR
T1 - Decreased Plasma Levels of Angiotensin-Converting Enzyme Among Patients With Bipolar Disorder
AU - Sanches, Marsal
AU - Colpo, Gabriela D.
AU - Cuellar, Valeria A.
AU - Bockmann, Taya
AU - Rogith, Deevakar
AU - Soares, Jair C.
AU - Teixeira, Antonio L.
N1 - Publisher Copyright:
© Copyright © 2021 Sanches, Colpo, Cuellar, Bockmann, Rogith, Soares and Teixeira.
PY - 2021/2/11
Y1 - 2021/2/11
N2 - Background: Dysfunctions in the renin-angiotensin system (RAS) seem to be involved in the pathophysiology of several mental illness, including schizophrenia and mood disorders. We carried out a cross-sectional study assessing the levels of RAS-related molecules among bipolar disorder (BD) patients compared to healthy controls. Methods: our sample consisted of 30 outpatients with BD type 1 (10 males, 20 females, age = 35.53 ± 10.59 years, 14 euthymic, 16 experiencing mood episodes) and 30 healthy controls (10 males, 20 females, age = 34.83 ± 11.49 years). Plasma levels of angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2), angiotensin-II (Ang II), and angiotensin (1–7) [Ang-(1–7)] were determined by ELISA. Results: BD patients experiencing ongoing mood episodes had significantly lower ACE levels compared to controls (median: 459.00 vs. 514.10, p < 0.05). There was no association between the levels of these biomarkers and clinical parameters. Conclusion: Our findings support the involvement of RAS dysfunction in the pathophysiology of BD. Considering the potential therapeutic implications linked to a better understanding of the role of RAS dysfunction in BD, studies allowing a better characterization of RAS-related molecules level and activity across different mood states are of high interest.
AB - Background: Dysfunctions in the renin-angiotensin system (RAS) seem to be involved in the pathophysiology of several mental illness, including schizophrenia and mood disorders. We carried out a cross-sectional study assessing the levels of RAS-related molecules among bipolar disorder (BD) patients compared to healthy controls. Methods: our sample consisted of 30 outpatients with BD type 1 (10 males, 20 females, age = 35.53 ± 10.59 years, 14 euthymic, 16 experiencing mood episodes) and 30 healthy controls (10 males, 20 females, age = 34.83 ± 11.49 years). Plasma levels of angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2), angiotensin-II (Ang II), and angiotensin (1–7) [Ang-(1–7)] were determined by ELISA. Results: BD patients experiencing ongoing mood episodes had significantly lower ACE levels compared to controls (median: 459.00 vs. 514.10, p < 0.05). There was no association between the levels of these biomarkers and clinical parameters. Conclusion: Our findings support the involvement of RAS dysfunction in the pathophysiology of BD. Considering the potential therapeutic implications linked to a better understanding of the role of RAS dysfunction in BD, studies allowing a better characterization of RAS-related molecules level and activity across different mood states are of high interest.
KW - angiotensin II
KW - angiotensin converting enzyme
KW - bipolar disorder
KW - depression
KW - mood disorders
KW - renin-angiotensin system
UR - http://www.scopus.com/inward/record.url?scp=85101933751&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101933751&partnerID=8YFLogxK
U2 - 10.3389/fnins.2021.617888
DO - 10.3389/fnins.2021.617888
M3 - Article
AN - SCOPUS:85101933751
SN - 1662-4548
VL - 15
JO - Frontiers in Neuroscience
JF - Frontiers in Neuroscience
M1 - 617888
ER -